Minerva Neurosciences reported $-5207000 in Operating Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US USD -30866000 2.78M
Adma Biologics ADMA:US USD 22.12M 31.29M
ALKERMES ALKS:US USD -60641000 26.18M
AstraZeneca AZN:LN USD 1.25B 706M
Biocryst Pharmaceuticals BCRX:US USD -17445000 17.28M
Bristol Myers Squibb BMY:US USD 1.94B 528M
Dynavax Technologies DVAX:US USD 61.4M 66.83M
Eli Lilly And LLY:US USD 1.84B 159.9M
Esperion Therapeutics ESPR:US USD -41623000 10.75M
GlaxoSmithKline GSK:LN GBP 1.87B 677M
Halozyme Therapeutics HALO:US USD 80.58M 46.52M
Johnson & Johnson JNJ:US USD 4.2B 1.62B
Marinus Pharmaceuticals MRNS:US USD -30099000 6.67M
Merk MRK:US USD 3.51B 505M
Minerva Neurosciences NERV:US USD -5207000 1.76M
Neurocrine Biosciences NBIX:US USD 87.8M 103.1M
Novartis NOVN:VX USD 2.17B 60M
Novavax NVAX:US USD -127189000 355.77M
Pfizer PFE:US USD 5.17B 4.24B
Roche Holding ROG:VX 11.55B 3.47B
Takeda 4502:JP JPY 146.99B 42.55B
Vanda Pharmaceuticals VNDA:US USD 3.91M 447K